Veracyte Quarterly Income Statement
NASDAQ: VCYTHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Veracyte revenue and earnings
In the quarter ended Jun 30, 2026, Veracyte generated $150.3 million in revenue, up 15.5% from the same quarter a year earlier. Net income was $25.5 million, for a net margin of 17.0% versus a median of 14.5% in the prior 5 quarters. Gross margin was 72.2% (up from 69.0%) and operating margin 15.3%.
Diluted earnings per share came in at $0.31.
Summary generated from market data by MetaCap's automated system. Methodology
Veracyte income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 150.32M | 139.07M | 140.64M | 131.87M | 130.16M | 114.47M | 118.63M | 115.86M | 114.43M | 96.84M | 98.20M | 90.11M |
| Revenue growth (YoY) | +15.49% | +21.49% | +18.55% | +13.82% | +13.75% | +18.20% | +20.81% | +28.58% | +26.69% | +17.50% | +22.29% | +19.20% |
| Gross Profit | 108.55M | 101.16M | 101.97M | 91.28M | 89.77M | 79.51M | 78.75M | 79.01M | 77.91M | 62.47M | 64.79M | 57.69M |
| Operating Expenses | 85.57M | 78.51M | 64.78M | 68.34M | 95.04M | 76.60M | 74.58M | 66.99M | 73.31M | 67.12M | 100.30M | 89.43M |
| Research & Development | 29.44M | 27.10M | 20.85M | 15.98M | 16.26M | 17.72M | 19.29M | 17.57M | 16.46M | 15.96M | 18.67M | 13.32M |
| Selling, General & Admin | 55.71M | 50.84M | 43.31M | 51.73M | 57.65M | 58.26M | 51.74M | 48.35M | 55.96M | 49.99M | 49.05M | 40.68M |
| Operating Income | 22.98M | 22.65M | 37.20M | 22.95M | -5.27M | 2.90M | 4.17M | 12.02M | 4.61M | -4.66M | -35.51M | -31.74M |
| Other Income (Expense) | 3.54M | 7.33M | 3.44M | -4.06M | 6.52M | 4.52M | -732.00K | 4.83M | 2.75M | 2.75M | 5.04M | 1.97M |
| Pretax Income | 26.52M | 29.97M | 40.63M | 18.89M | 1.25M | 7.43M | 3.44M | 16.85M | 7.36M | -1.91M | -30.47M | -29.77M |
| Income Tax | 1.03M | 1.27M | -515.00K | -248.00K | 2.23M | 381.00K | -1.67M | 1.69M | 1.63M | -44.00K | -2.18M | -154.00K |
| Net Income | 25.49M | 28.71M | 41.15M | 19.14M | -980.00K | 7.05M | 5.11M | 15.15M | 5.73M | -1.86M | -28.29M | -29.62M |
| Net Income growth (YoY) | — | +307.36% | +704.79% | +26.28% | -117.09% | — | — | — | — | — | — | — |
| EPS (Basic) | 0.32 | 0.36 | 0.52 | 0.24 | -0.01 | 0.09 | 0.07 | 0.20 | 0.07 | -0.02 | -0.38 | -0.41 |
| EPS (Diluted) | 0.31 | 0.35 | 0.50 | 0.24 | -0.01 | 0.09 | 0.07 | 0.19 | 0.07 | -0.02 | -0.38 | -0.41 |
| Shares Outstanding (Basic) | 79.97M | 79.54M | — | 78.73M | 78.39M | 78.03M | — | 77.01M | 76.54M | 74.76M | — | 72.80M |
| Shares Outstanding (Diluted) | 82.06M | 81.31M | — | 79.69M | 78.39M | 80.06M | — | 78.46M | 77.16M | 74.76M | — | 72.80M |
| EBITDA | 27.82M | 28.08M | 42.49M | 28.21M | 221.00K | 8.27M | 10.43M | 17.89M | 10.34M | 934.00K | -29.17M | -24.42M |
| Gross Margin | 72.21% | 72.74% | 72.51% | 69.22% | 68.97% | 69.46% | 66.39% | 68.19% | 68.09% | 64.50% | 65.98% | 64.02% |
| Operating Margin | 15.29% | 16.28% | 26.45% | 17.40% | -4.05% | 2.54% | 3.52% | 10.37% | 4.03% | -4.81% | -36.16% | -35.22% |
| Net Margin | 16.96% | 20.64% | 29.26% | 14.51% | -75.00% | 6.16% | 4.31% | 13.08% | 5.01% | -1.92% | -28.81% | -32.87% |
This table shows 12 quarterly periods of Veracyte's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow VCYT's reporting calendar. What is a income statement?